North Wales, PA, United States of America

Steven W Ludmerer

USPTO Granted Patents = 16 (Patent Applications = 5)

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 3.6

ph-index = 6

Forward Citations = 148(Granted Patents)

Location History:

Pisataway, NJ (US) (1998)
Picataway, NJ (US) (1998)
Piscataway, NY (US) (1999)
Piscataway, NJ (US) (1999 - 2006)
North Wales, PA (US) (2008 - 2021)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

1 out of 8

Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.a.

patents

where one patent can have more than one assignee

Years Active: 1998-2021

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11053243 - Inhibitors of hepatitis C virus replication (2021-07-06),

2. 9090661 - Inhibitors of hepatitis C virus replication (2015-07-28),

3. 8871759 - Inhibitors of hepatitis C virus replication (2014-10-28),

4. 8354518 - HCV replicons containing NS5B from genotype 2B (2013-01-15),

5. 8278322 - HCV NS3 protease inhibitors (2012-10-02),

6. 8216999 - HCV NS3 protease inhibitors (2012-07-10),

7. 7879797 - HCV NS3 protease inhibitors (2011-02-01),

8. 7569374 - HCV RNA-dependent RNA polymerase (2009-08-04),

9. 7470664 - HCV NS3 protease inhibitors (2008-12-30),

10. 7329732 - HCV RNA-dependent RNA polymerase (2008-02-12),

11. 7033797 - Synthetic virus-like particles with heterologous epitopes (2006-04-25),

12. 6689366 - Synthetic virus like particles with heterologous epitopes (2004-02-10),

13. 5952216 - Synthetic HPV 16 virus-like particles (1999-09-14),

14. 5922588 - Synthetic HPV16 virus-like particles (1999-07-13),

15. 5795754 - Synthetic HPV11 virus-like particles (1998-08-18),

Title: The Innovative Contributions of Steven W. Ludmerer

Introduction: Steven W. Ludmerer, based in North Wales, Pennsylvania, is a prominent inventor known for his substantial contributions to the field of pharmaceuticals. With a remarkable portfolio of 16 patents, Ludmerer's work significantly impacts the medical community, particularly in the fight against hepatitis C virus infections.

Latest Patents: Among his latest innovations are two notable patents related to inhibitors of hepatitis C virus replication. These inventions introduce compounds that serve as NS5A inhibitors, essential for curtailing HCV activity. The synthesis and application of these compounds target the inhibition of HCV viral replication and production within cell-based systems, showcasing Ludmerer's commitment to advancing therapeutic solutions.

Career Highlights: Ludmerer has a distinguished career, having worked with leading companies in the pharmaceutical industry, including Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His experience in these reputable organizations has shaped his expertise and enabled him to develop innovative solutions to urgent health challenges.

Collaborations: Throughout his career, Steven has collaborated with influential figures in the industry, including coworkers John A. McCauley and Joseph P. Vacca. These collaborations reflect the synergy of expertise that fuels successful innovations in drug development and healthcare.

Conclusion: As an inventor, Steven W. Ludmerer exemplifies the spirit of innovation in the pharmaceutical field. His contributions through patents indicate a dedicated pursuit of solutions to complex health issues, particularly hepatitis C. With a legacy that includes collaboration and significant advancements, Ludmerer continues to inspire future generations of inventors and researchers.

This text is generated by artificial intelligence and may not be accurate.